Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in ...

INR:4518. new edition bet awards performance How to prevent and treat the return of Ebola? Can it be cured? FDA updates ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

The United States will try to defend its title when the 2025 IIHF World Junior Championship begins Thursday in Ottawa. The United States won the 2024 WJC, defeating Sweden 6-2 in the gold medal ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.